Nycomed gains FDA clearance for EchoSeed:
This article was originally published in Clinica
The US FDA has cleared for sale Nycomed Amersham's new brachytherapy seed for treating prostate cancer. EchoSeed (iodine-125) incorporates a patented grooved design and is implanted under the guidance of ultrasound imaging, facilitating optimal placement into the prostate, says the Buckinghamshire, UK firm, which will soon be known simply as Amersham. The product was launched this week at the American Urological Association meeting in Anaheim, California.